HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
B 464 (B464)
a synthetic lipopolysaccharide antagonist
Also Known As:
B464
; B-464
Networked:
1
relevant articles (
0
outcomes,
0
trials/studies)
Bio-Agent Context: Research Results
Carbohydrates: 22023
Polysaccharides: 15383
Bacterial Polysaccharides: 50
Lipopolysaccharides: 27188
Lipid A: 699
B 464: 1
Lipids: 114793
Lipopolysaccharides: 27188
Lipid A: 699
B 464: 1
Biological Factors: 2472
Antigens: 143924
Bacterial Antigens: 807
Bacterial Polysaccharides: 50
Lipopolysaccharides: 27188
Lipid A: 699
B 464: 1
Biological Toxins: 20
Bacterial Toxins: 814
Endotoxins: 14335
Lipopolysaccharides: 27188
Lipid A: 699
B 464: 1
Related Diseases
1.
Acute Lung Injury
10/01/1996 - "
These in vivo data, together with in vitro evidence of suppressed cellular responses, suggest that B464 (1) inhibits neutrophil accumulation in lung tissue, and (2) attenuates the development of acute lung injury by blocking the activation of neutrophils and mononuclear cells as well as the interaction between neutrophils and endothelial cells.
"
10/01/1996 - "
We then studied the effects of B464 pretreatment on acute lung injury elicited by intravenous LPS administration in vivo.
"
10/01/1996 - "
We investigated the effects of B464 on both LPS-induced cellular responses in vitro and acute lung injury in vivo.
"
10/01/1996 - "
Protective effect of B464, a lipid A analog, on endotoxin-induced cellular responses and acute lung injury.
"
2.
Lung Injury
10/01/1996 - "
In the LPS + B464 group, no changes were observed in either plasma TNF-alpha or lung injury parameters.
"
3.
Neutropenia
10/01/1996 - "
Transient peripheral neutropenia and subsequent rapid recovery (p > 0.05, p < 0.001, p < 0.01, and p > 0.05 at 15 min and 1, 2, and 4 h, respectively) were observed in the LPS + B464 group.
"
Related Drugs and Biologics
1.
Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
2.
Lipid A
3.
Endotoxins